These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 30558570)

  • 1. Treatment of hemolytic uremic syndrome related to Bordetella pertussis infection -is plasma exchange or eculizumab use necessary?
    Saida K; Ogura M; Kano Y; Ishimori S; Yoshikawa T; Nagata H; Sato M; Kamei K; Ishikura K
    BMC Nephrol; 2018 Dec; 19(1):365. PubMed ID: 30558570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemolytic uremic syndrome associated with Bordetella pertussis infection in a 2-month-old infant carrying a pathogenic variant in complement factor H.
    Madden I; Roumenina LT; Langlois-Meurinne H; Guichoux J; Llanas B; Frémeaux-Bacchi V; Harambat J; Godron-Dubrasquet A
    Pediatr Nephrol; 2019 Mar; 34(3):533-537. PubMed ID: 30560448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemolytic uremic syndrome caused by Bordetella pertussis infection.
    Chaturvedi S; Licht C; Langlois V
    Pediatr Nephrol; 2010 Jul; 25(7):1361-4. PubMed ID: 20145955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma resistant atypical hemolytic uremic syndrome associated with a CFH mutation treated with eculizumab: a case report.
    Sevinc M; Basturk T; Sahutoglu T; Sakaci T; Koc Y; Ahbap E; Akgol C; Kara E; Brocklebank V; Goodship TH; Kavanagh D; Unsal A
    J Med Case Rep; 2015 Apr; 9():92. PubMed ID: 25925370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of eculizumab and plasma exchange in successful combined liver-kidney transplantation in a case of atypical HUS associated with complement factor H mutation.
    Tran H; Chaudhuri A; Concepcion W; Grimm PC
    Pediatr Nephrol; 2014 Mar; 29(3):477-80. PubMed ID: 24221349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pediatric neurologic assessment score may drive the eculizumab-based treatment of Escherichia coli-related hemolytic uremic syndrome with neurological involvement.
    Giordano P; Netti GS; Santangelo L; Castellano G; Carbone V; Torres DD; Martino M; Sesta M; Di Cuonzo F; Resta MC; Gaeta A; Milella L; Chironna M; Germinario C; Scavia G; Gesualdo L; Giordano M
    Pediatr Nephrol; 2019 Mar; 34(3):517-527. PubMed ID: 30362078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemolytic uremic syndrome with dual caution in an infant: cobalamin C defect and complement dysregulation successfully treated with eculizumab.
    Barlas UK; Kıhtır HS; Goknar N; Ersoy M; Akcay N; Sevketoglu E
    Pediatr Nephrol; 2018 Jun; 33(6):1093-1096. PubMed ID: 29558000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors.
    Le Clech A; Simon-Tillaux N; Provôt F; Delmas Y; Vieira-Martins P; Limou S; Halimi JM; Le Quintrec M; Lebourg L; Grangé S; Karras A; Ribes D; Jourde-Chiche N; Rondeau E; Frémeaux-Bacchi V; Fakhouri F
    Kidney Int; 2019 Jun; 95(6):1443-1452. PubMed ID: 30982675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemolytic uremic syndrome in an infant following Bordetella pertussis infection.
    Pela I; Seracini D; Caprioli A; Castelletti F; Giammanco A
    Eur J Clin Microbiol Infect Dis; 2006 Aug; 25(8):515-7. PubMed ID: 16871374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens.
    Krishnappa V; Gupta M; Elrifai M; Moftakhar B; Ensley MJ; Vachharajani TJ; Sethi SK; Raina R
    Ther Apher Dial; 2018 Apr; 22(2):178-188. PubMed ID: 29250893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemolytic uremic syndrome due to an altered factor H triggered by neonatal pertussis.
    Berner R; Krause MF; Gordjani N; Zipfel PF; Boehm N; Krueger M; Brandis M; Zimmerhackl LB
    Pediatr Nephrol; 2002 Mar; 17(3):190-2. PubMed ID: 11956859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement Inhibitors in the Management of Complement-Mediated Hemolytic Uremic Syndrome and Paroxysmal Nocturnal Hemoglobinuria.
    Begum F; Khan N; Boisclair S; Malieckal DA; Chitty D
    Am J Ther; 2023 May; 30(3):e209-e219. PubMed ID: 37104648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Typical or Atypical Hemolytic Uremic Syndrome and the Use of Eculizumab: 4 Illustrative Cases.
    de Ville de Goyet M; Detaille T; Godefroid N
    J Pediatr Hematol Oncol; 2019 Oct; 41(7):e459-e462. PubMed ID: 30933023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome.
    Zuber J; Frimat M; Caillard S; Kamar N; Gatault P; Petitprez F; Couzi L; Jourde-Chiche N; Chatelet V; Gaisne R; Bertrand D; Bamoulid J; Louis M; Sberro Soussan R; Navarro D; Westeel PF; Frimat L; Colosio C; Thierry A; Rivalan J; Albano L; Arzouk N; Cornec-Le Gall E; Claisse G; Elias M; El Karoui K; Chauvet S; Coindre JP; Rerolle JP; Tricot L; Sayegh J; Garrouste C; Charasse C; Delmas Y; Massy Z; Hourmant M; Servais A; Loirat C; Fakhouri F; Pouteil-Noble C; Peraldi MN; Legendre C; Rondeau E; Le Quintrec M; Frémeaux-Bacchi V
    J Am Soc Nephrol; 2019 Dec; 30(12):2449-2463. PubMed ID: 31575699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eculizumab Modifies Outcomes in Adults with Atypical Hemolytic Uremic Syndrome with Acute Kidney Injury.
    Cao M; Leite BN; Ferreiro T; Calvo M; Fernández C; Alonso Á; Rodriguez A; Salvador P; Seijo R; Pita S; Arjona E; Rodríguez de Córdoba S; Valdés Cañedo F
    Am J Nephrol; 2018; 48(3):225-233. PubMed ID: 30205388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [HELLP syndrome and hemolytic uremic syndrome during pregnancy: two disease entities, same causation. Case report and literature review].
    Mancini A; Ardissino G; Angelini P; Giancaspro V; La Raia E; Nisi M; Proscia A; Tarantino G; Vitale O; D'elia F
    G Ital Nefrol; 2019 Apr; 36(2):. PubMed ID: 30983177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report.
    Yamamoto T; Watarai Y; Futamura K; Okada M; Tsujita M; Hiramitsu T; Goto N; Narumi S; Takeda A; Kobayashi T
    Transplant Proc; 2017; 49(1):159-162. PubMed ID: 28104125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A case of atypical hemolytic uremic syndrome successfully weaned from plasma exchange by treatment with eculizumab].
    Nagata A; Ohara A; Wakasugi D; Natori C; Ito S; Taguchi K; Fukami K; Okuda S
    Nihon Jinzo Gakkai Shi; 2014; 56(5):606-11. PubMed ID: 25130033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemolytic Uremic Syndrome in Pregnancy and Postpartum.
    Bruel A; Kavanagh D; Noris M; Delmas Y; Wong EKS; Bresin E; Provôt F; Brocklebank V; Mele C; Remuzzi G; Loirat C; Frémeaux-Bacchi V; Fakhouri F
    Clin J Am Soc Nephrol; 2017 Aug; 12(8):1237-1247. PubMed ID: 28596415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.
    Legendre CM; Licht C; Muus P; Greenbaum LA; Babu S; Bedrosian C; Bingham C; Cohen DJ; Delmas Y; Douglas K; Eitner F; Feldkamp T; Fouque D; Furman RR; Gaber O; Herthelius M; Hourmant M; Karpman D; Lebranchu Y; Mariat C; Menne J; Moulin B; Nürnberger J; Ogawa M; Remuzzi G; Richard T; Sberro-Soussan R; Severino B; Sheerin NS; Trivelli A; Zimmerhackl LB; Goodship T; Loirat C
    N Engl J Med; 2013 Jun; 368(23):2169-81. PubMed ID: 23738544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.